wound cultures and sensitivities, and the role of infectious disease consultation. The available literature relating to previously-described ATM infections was also reviewed and evaluated. Diagnosis, surgical treatment, infectious disease consultation, and medicolegal management issues relating to ATM infections are detailed and discussed.
Patient 1
A 55-year-old woman with symptomatic macromastia presented for bilateral reduction mammaplasty. Her past history was significant for prior benign breast biopsies and tobacco use. Her right breast was asymmetrically larger than the left, with grade III ptosis bilaterally. She underwent uncomplicated Wise-pattern reduction mammaplasty with 560 grams and 520 grams of breast tissue resected from the right and left breasts, respectively. Her initial wound healing was normal. Two weeks postoperatively, the patient called the office complaining of small amounts of clear drainage from the periareolar closure of the right breast. She was placed on amoxicillin-clavulanate and instructed to follow up in our office later that week. On presentation, she had two small abscesses that had opened in the prior scars, one periareolar and one in the inframammary closure. These healed over the following three weeks. Nine weeks postoperatively, the patient presented with increasing pain and evidence of fluid collection in the inframammary area. This abscess was incised and drained, and the fluid was sent for cultures. The patient was placed on levofloxacin and the site was packed open. One week later, the patient returned with an additional area of periareolar dehiscence. Her prior gram stains showed possible acid-fast bacilli. The patient was then referred to an infectious disease specialist for assistance with management. The cultures eventually grew M. fortuitum and the patient was prescribed a course of clarithromycin and Figure 1 ).
Patient 2
A 73-year-old woman with symptomatic macromastia presented for bilateral reduction mammaplasty. She had grade III ptosis, with her left breast asymmetrically larger than the right. She underwent an uncomplicated Wisepattern reduction with 380 grams and 540 grams of tissue were removed from the right and left breasts, respectively. She did well postoperatively, with normal wound healing. She returned to the office nine months postoperatively complaining of a mass on her medial left breast. On initial evaluation, the mass appeared to be an infected fluid collection or sebaceous cyst. Incision and drainage was performed, and the patient was prescribed amoxicillinclavulanate. Another area in the central vertical scar opened and began to drain two weeks later. This area was also incised, drained, and cultured. The initial culture showed only a contaminant. However, the second set of cultures grew M. fortuitum. Infectious disease consultation was obtained and the patient began a course of clarithromycin for four to six months. She tolerated this well, her open lesions healed, and the infection cleared. Unfortunately, one month later, she had a new area of drainage. New cultures were obtained and her antibiotic therapy changed to trimethoprim-sulfamethoxazole and levofloxacin. Further operative debridement was performed to clear these areas of refractory infection. The areas of prior drainage were also resected, including a tract from the middle periareolar area. Following her last debridement and an additional six weeks of antibiotic treatment, the patient healed without any signs or symptoms of residual infection. Accusations of mismanagement and other threats of litigation continued until the definitive diagnosis was obtained (see Figure 2 ).
Patient 3
A 27-year-old woman with symptomatic macromastia and breast asymmetry presented for breast reduction. She was otherwise healthy, with the exception of a prior fullthickness burn with extensive scarring over 60% of her left breast. The patient underwent uncomplicated bilateral Wise-pattern reduction mammaplasty. Resection weights were 1200 grams on the right and 850 grams on the left. Ten days postoperatively, she returned with small areas of drainage from the inferior portion of the left breast and a course of cephalexin was started. One month later, a small area of dehiscence had developed, along with a fluctuant mass. This was incised and drained, and ciprofloxacin was initiated. She continued to experience increased drainage along the inframammary fold. An ultrasound of the breast was obtained, showing multiple serous fluid collections. On the basis of her clinical progression as well as the ultrasound evidence, the patient was admitted to the hospital for intravenous antibiotics and formal exploration and debridement. Multiple sites were opened, debrided, and packed. On follow-up, the patient appeared to be doing very well and was healing by secondary intention. However, one month later, she returned with recurrent drainage. Repeat ultrasound showed recurrent fluid collection and an interventional radiology specialist placed a drain into the main cavity. Drainage persisted and the patient was placed on antifungal medication by infectious disease to maximally broaden coverage. All cultures remained negative to this point. The patient underwent a second and finally a definitive third operative debridement. Tissue cultures from this last debridement grew M. chelonei and the patient was started on clarithromycin by an infectious disease specialist. The patient then returned six months later, again with recurrent swelling and drainage in left upper breast. New cultures returned with sensitivities showing the strain of M. chelonei to be highly resistant, except to quinolones. She followed up with the infectious disease department and was initiated on a regimen of ciprofloxacin and azithromycin, finally healing nearly one year after her initial surgery. Throughout the patient's extended course of diagnosis and treatment, she had been referred to multiple additional plastic surgeons and infectious disease physicians for second opinions. However, as before, there were accusations of mismanagement and lawsuits were threatened throughout the prolonged process (Figures 3 and 4) . 
DiSCuSSion
ATM infections have been described in association with augmentation mammaplasty. Infection usually involves the implant, often resulting in removal of the device and significant morbidity. In addition, there are less-frequentlydescribed infections associated with other aesthetic procedures, including liposuction and rhytidectomy. 10, 11 Outbreaks of ATM infections have also been reported in US patients traveling abroad for surgery, particularly in lay clinics. 12 Furthermore, there have also been scattered reports of ophthalmologic operative infections. 13 Although M. fortuitum is known to cause cutaneous infections, this is the first case series of M. fortuitum complex infections of the breast where an implant was not involved. One breast reduction case was briefly alluded to in an anonymous survey and one report of an infection associated with "breast ptosis correction" has been reported, although the exact nature of the procedure was not described. 6, 14 In addition, there was a single description of an infection involving reconstruction with a latissimus flap. 15 Therefore, we believe this to be the first formal description and discussion of a series of ATM infections following reduction mammaplasty.
In light of these reports, practitioners should have a high level of suspicion for an ATM infection when managing any nonhealing or recurrent postoperative breast infection. If the patient heals primarily and then develops a delayed infection weeks to months later, surgeons should investigate for possible ATM infection. As this pathogen is rare, requires specialized growth mediums for detection, and is treated with antibiotics that are not first-line wound infection drugs, the surgeon must actively consider this pathogen in his or her differential diagnosis in order to diagnose and treat in a timely fashion. If ATM is not in the differential diagnosis until late in the course, there can be a substantial delay in diagnosis and treatment.
Although the overall infection rate with ATM is unknown, these patients represent approximately 0.13% (3/2200) of patients in the authors' two practices who have undergone breast reductions over the past 12 years. In addition, there is an even lower incidence when considering the entire Grand Rapids area, as no other ATM infections (with the exception of two related to breast implants) have been documented or reported.
Previous descriptions and presentations of M. fortuitum complex have demonstrated a high degree of variability. Similarly, our cases also showed great variability in their timing and presentation, presenting from two weeks to nine months postoperatively. Although some typical wound infections may present at two weeks, presentation at nine months postoperatively would be exceptionally delayed. Most classic wound infections should be evident within a few days to a week following surgery. Because these are atypical pathogens, many clinicians are unfamiliar with their presentation pattern and timing.
All of our patients received antibiotics and had serouslike fluid collections requiring drainage. The fluid is an Table 3 . Common Antibiotics for Treating ATM Infection
Clarithromycin is the traditional first-line choice for initial antibiotic therapy.
unusual gray-to-clear, nonmalodorous drainage. The infections also commonly track with eruption in areas of prior scars. Clarithromycin is one of the classic first-line drugs for ATM infection and the drug often first initiated by infectious disease consultants. Other antibiotics classically employed include fluoroquinolones, amikacin, minocycline, and trimethoprim-sulfamethoxazole (Table 3) . Unfortunately, increasing development of resistance to clarithromycin monotherapy has been reported. 16 The pathogen in our first patient was found to be resistant to clarithromycin. Sensitivities were available in the early stages and this infection cleared without operative debridement after initiation of correct antibiotics. The two other patients required formal operative debridement after ultimately failing antibiotic therapy alone, with one patient requiring multiple debridements. One of these patients also was eventually proven to carry a clarithromycinresistant strain, further emphasizing the importance of early, accurate sensitivities. Delayed or unavailable sensitivities ultimately hinder effective treatment and potentially increase the likelihood of requiring operative debridement. However, the literature does clearly support early surgical debridement as a standard approach to these infections, along with targeted sensitivity-based antibiotic therapy. [17] [18] [19] These cases confirm that long-term targeted antibiotic therapy based on accurate, early sensitivities along with operative debridement as necessary can effect cure.
These patients were part of two separate practices, were operated on at two different sites, and were spread over a nearly 12-year period. As a result, we have been unable to find commonality between them in trying to establish a source or cause. There does not seem to be anything inherent about the patients, locations, or surgeons that may have predisposed our patients to these infections. Established risk factors such as immunocompromise were never found to be present in any of our patients. However, two of our patients had undergone prior breast surgery and one had a severe burn. There was also reported tobacco use in one patient and diabetes in another. It is conceivable that these prior injuries and procedures, as well as comorbidities, may have played a role in facilitating infection. When an immunologicallycompromised patient, or a patient with prior trauma or significant scarring, experiences postoperative infection that does not respond to standard antibiotic therapy, ATM should be considered.
As seen in two of our cases, when a patient heals normally and then develops a delayed infection or does not respond to formal debridement and antimicrobial therapy, accusations of malpractice and even threats of litigation may occur. Directed second opinions from additional plastic surgeons and infectious disease consultations are recommended to both assist in diagnosis and treatment, as well as to defuse allegations.
ConCluSionS
This report represents the first case series of atypical mycobacterial infections of the breast without an associated breast implant. The M. fortuitum complex involves atypical acid-fast bacilli previously described in our literature, in association with wound infections related to breast implants. Our three cases of breast infection following reduction mammaplasty reveal the need for plastic surgeons to have a high level of suspicion for these atypical bacteria in any postoperative breast infection that is refractory to first-line diagnosis and therapy (see Tables 4 and 5 ). Early culture and sensitivity information will prove invaluable in directing specific antibiotic therapy and operative intervention. The keys to eliminating these infections are long-term targeted antibiotic therapy (often six to eight weeks in length), adequate surgical drainage and debridement, and a multidisciplinary approach in consultation with infectious disease specialists.
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